Skip to main content
  • Saved

made a Post

Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience

Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience

Source :

https://www.tandfonline.com/doi/abs/10.1080/1744666X.2022.2106972?journalCode=ierm20

ABSTRACT Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day. Efgartigimod is a human IgG1-derived Fc fragment modified at five residues to increase its affinity for the neonatal Fc receptor by Abdeg technology.


Expert Opinion: Efgartigimod was efficacious and safe for generalized myasthenia patients with AChR antibody-positive patients. These findings need to be confirmed in AChR antibody-negative patients, and long-term safety studies are currently ongoing.